Quantcast

Industry news that matters to you.  Learn more

Arizona Invests $2.2 Million for New Biosignature Laboratory

Governor Jan Brewer announced the awarding of $2.2 million to Science Foundation Arizona in order support the creation of an Arizona Biosignature Laboratory that will focus on research into major diseases including lung cancer, Alzheimer’s and kidney diseases.

Simple Blood Test May Detect Alzheimer’s: TTUHSC Researcher Featured in JAMA

The September issue of Archives of Neurology, one of the JAMA/Archives journals, features research, which finds that a simple blood test could diagnose Alzheimer’s disease.

Consortium Develops Algorithm from Blood-Based Alzheimer’s Biomarkers

In a study appearing in the newest issue of the Archives of Neurology, members of the Texas Alzheimer’s Research Consortium reported that they have identified protein biomarkers in the blood that can be used to distinguish between individuals with and without Alzheimer’s disease.

Plavix Biomarker Test Can Improve Patient Outcomes

In January, the Agency for Healthcare Research and Quality (AHRQ) released “Outpatient Prescription Anticoagulants Utilization and Expenditures for the U.S. Civilian Noninstitutionalized Population Age 18 and Older 2007,” a study from its October 2009 Medical Expenditure Panel Survey (MEPS). This report found that anticoagulant drugs were prescribed to more than 4.2 million Americans at a cost of $900 million and were paid for by patients and/or third-party payers.

Spinal-Fluid Test Is Found to Predict Alzheimer’s

Researchers report that a spinal fluid test can be 100 percent accurate in identifying patients with significant memory loss who are on their way to developing Alzheimer’s disease.

Although there has been increasing evidence of the value of this and other tests in finding signs of Alzheimer’s, the study, which will appear Tuesday in the Archives of Neurology, shows how accurate they can be. The new result is one of a number of remarkable recent findings about Alzheimer’s.

After decades when nothing much seemed to be happening, when this progressive brain disease seemed untreatable and when its diagnosis could be confirmed only at autopsy, the field has suddenly woken up.